Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a driving simulator spot stoned drivers? new study investigates

NCT ID NCT06255054

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at how cannabis affects driving by using a driving simulator. Researchers compared the driving performance of 207 adults who use cannabis daily, occasionally, or not at all. The goal was to better understand different levels of impairment and improve road safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help develop better ways to detect cannabis-impaired driving and improve road safety.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly lead to a new therapy. Results may not apply to all drivers or real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

207 people

The number who actually took part.

Started

Jun 2020

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Potential participants will be recruited from the general population.

Ages

25 to 55 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The following are inclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Participants who are ≥21 years old and ≤55 years old 2. Participants who are able to provide written, informed consent 3. Participants with active healthcare coverage (including health insurance, Medicaid, etc.) 4. Participants who are willing to complete up to two in-person study visits (one for Phases 1 \& 2, and two for Phases 3 \& 4), including up to two urine drug screens, two alcohol breathalyzer tests, and one urine pregnancy test (if applicable) 5. Participants who agree to refrain from using non-prescription psychotropic drugs (e.g., ecstasy), hallucinogens, and synthetic cannabinoids during the study 6. Participants who agree to refrain from drinking \>3 alcoholic drinks the day prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 7. Participants who agree to refrain from using any cannabis products for at least 8 hours prior to the data collection study visit (the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 8. Participants who are willing to provide and use their own cannabis product that has been procured from a licensed dispensary, is labeled with THC potency, and contains \<2% CBD (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 9. Participants who agree to have a sober driver pick them up after the data collection study visit (cannabis use groups only; the single visit for Phases 1 \& 2, and the second visit for Phases 3 \& 4) 10. Participants who take at least 2 inhalations ("hits") during their typical inhalational (smoking/vaporizing) sessions, or ingest at least 5 mg of THC when they consume edible cannabis products (cannabis use groups only) 11. Participants who are willing to provide a sample of their cannabis to be independently tested for potency and terpene content (Phases 1, 3 \& 4 only) Exclusion Criteria: * The following are exclusion criteria for participants to be enrolled in any of the four phases of the study: 1. Prisoners 2. Participants who have nocturnal schedules (e.g., work night shifts) 3. Participants with a history of abuse or addiction to substances other than cannabis (e.g., prescription and non-prescription pharmaceuticals, alcohol, or illicit drugs) 4. Participants who have expressed an interest in substance abuse treatment within the 60 days prior to study enrollment 5. Participants who report consuming an average of \>3 alcoholic drinks per day in the 30 days prior to study enrollment 6. Participants with any past or current diagnosis of schizophrenia, narcolepsy, heart disease, epilepsy, or a traumatic brain injury 7. Participants who are currently experiencing untreated bipolar disorder, major depression, sleep apnea, or other uncontrolled medical conditions as determined by the investigators (e.g., hypertension) 8. Participants with a known balance or gait disorder 9. Participants with color blindness (Phase 2 only) 10. Participants who currently wear hard contact lenses for vision correction (Phase 2 only) 11. Participants who have donated 450 mL or more of blood in the two weeks prior to study enrollment 12. Participants who are pregnant or breastfeeding (female participants only) 13. Participants who report never using cannabis before in their lifetime (Phases 1 \& 2 only) 14. Participants with a history of clinically significant adverse event(s) associated with cannabis intoxication (e.g., lightheadedness, nausea, dizziness, etc., cannabis use groups only) 15. Participants with uncorrected visual acuity disorder, defined as binocular vision worse than 20/40 (Phases 2, 3 \& 4 only; determined at screening) 16. Participants with a body mass index \>40 kg/m2 (determined at screening) 17. Participants with a positive breath alcohol test (breathalyzer) at screening 18. Participants who are otherwise unsuitable for inclusion in the study, based on the opinion of the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Driving Study Lab

    Denver, Colorado, 80220, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.